PPPatricia Palacios

Patricia Palacios

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Patricia Palacios has a total of 26 co-authors. Here are the top co-authors by number of shared publications:

  • Rafael López-López

    Translational Medical Oncology Group, Oncomet. Health Research Institute of Santiago de Compostela, Santiago de Compostela, Spain

    4 shared publications
  • Carmen Abuín

    Roche-Chus Joint Unit, Translational Medical Oncology Group, Oncomet, Health Research Institute of Santiago de Compostela, Travesía da Choupana s/n, 15706 Santiago de Compostela, Spain

    3 shared publications
  • Clotilde Costa

    Translational Medical Oncology Group, Oncomet. Health Research Institute of Santiago de Compostela, Santiago de Compostela, Spain

    3 shared publications
  • Juan Cueva

    Department of Oncology, Complexo Hospitalario Universitario de Santiago de Compostela (SERGAS), 15706 Santiago de Compostela, Spain

    3 shared publications
  • Alicia Abalo

    Translational Medical Oncology (Oncomet)/ Liquid Biopsy Analysis Unit, Health Research Institute of Santiago (IDIS), Complexo Hospitalario Universitario de Santiago de Compostela, 15706, Santiago de Compostela, Spain

    2 shared publications
  • Laura Muinelo-Romay

    Translational Medical Oncology (Oncomet)/ Liquid Biopsy Analysis Unit, Health Research Institute of Santiago (IDIS), Complexo Hospitalario Universitario de Santiago de Compostela, 15706, Santiago de Compostela, Spain

    2 shared publications

Latest Publications

  • Open Access

    Exercise-based cardio-oncology rehabilitation for cardiotoxicity prevention during breast cancer chemotherapy: The ONCORE randomized controlled trial

    by Estíbaliz Díaz-Balboa, Carlos Peña-Gil, Beatriz Rodríguez-Romero, Antonio I. Cuesta-Vargas, Oscar Lado-Baleato, Amparo Martínez-Monzonís, Milagros Pedreira-Pérez, Patricia Palacios-Ozores, Rafael López-López, José R. González-Juanatey, et al.


  • Open Access

    Short-Term Ex Vivo Culture of CTCs from Advance Breast Cancer Patients: Clinical Implications

    by Nuria Carmona-Ule, Miriam González-Conde, Carmen Abuín, Juan F. Cueva, Patricia Palacios, Rafael López-López, Clotilde Costa, Ana Belén Dávila-Ibáñez

    Background: Circulating tumor cells (CTC) have relevance as prognostic markers in breast cancer. However, the functional properties of CTCs or their molecular characterization have not been well-studied. Experimental models indicate that only a few cells can survive in the circulation and eventually metastasize. Thus, it is essential to identify these surviving cells capable of forming such metastases. Methods: We isolated viable CTCs from 50 peripheral blood samples obtained from 35 patients with advanced metastatic breast cancer using RosetteSepTM for ex vivo culture. The CTCs were seeded and monitored on plates under low adherence conditions and with media supplemented with growth factors and Nanoemulsions. Phenotypic analysis was performed by immunofluorescence and gene expression analysis using RT-PCR and CTCs counting by the Cellsearch® system. Results: We found that in 75% of samples the CTC cultures lasted more than 23 days, predicting a shorter Progression-Free Survival in these patients, independently of having ≥5 CTC by Cellsearch®. We also observed that CTCs before and after culture showed a different gene expression profile. Conclusions: the cultivability of CTCs is a predictive factor. Furthermore, the subset of cells capable of growing ex vivo show stem or mesenchymal features and may represent the CTC population with metastatic potential in vivo.


  • Open Access

    Analysis of a Real-World Cohort of Metastatic Breast Cancer Patients Shows Circulating Tumor Cell Clusters (CTC-clusters) as Predictors of Patient Outcomes

    by Clotilde Costa, Laura Muinelo-Romay, Victor Cebey-López, Thais Pereira-Veiga, Inés Martínez-Pena, Manuel Abreu, Alicia Abalo, Ramón M. Lago-Lestón, Carmen Abuín, Patricia Palacios, et al.

    Circulating tumor cell (CTC) enumeration has emerged as a powerful biomarker for the assessment of prognosis and the response to treatment in metastatic breast cancer (MBC). Moreover, clinical evidences show that CTC-cluster counts add prognostic information to CTC enumeration, however, their significance is not well understood, and more clinical evidences are needed. We aim to evaluate the prognostic value of longitudinally collected single CTCs and CTC-clusters in a heterogeneous real-world cohort of 54 MBC patients. Blood samples were longitudinally collected at baseline and follow up. CTC and CTC-cluster enumeration was performed using the CellSearch® system. Associations with progression-free survival (PFS) and overall survival (OS) were evaluated using Cox proportional hazards modelling. Elevated CTC counts and CTC-clusters at baseline were significantly associated with a shorter survival time. In joint analysis, patients with high CTC counts and CTC-cluster at baseline were at a higher risk of progression and death, and longitudinal analysis showed that patients with CTC-clusters had significantly shorter survival compared to patients without clusters. Moreover, patients with CTC-cluster of a larger size were at a higher risk of death. A longitudinal analysis of a real-world cohort of MBC patients indicates that CTC-clusters analysis provides additional prognostic value to single CTC enumeration, and that CTC-cluster size correlates with patient outcome.


  • Open Access

    CTCs Expression Profiling for Advanced Breast Cancer Monitoring

    by Thais Pereira-Veiga, Mónica Martínez-Fernández, Carmen Abuin, Roberto Piñeiro, Victor Cebey, Juan Cueva, Patricia Palacios, Cristina Blanco, Laura Muinelo-Romay, Alicia Abalo, et al.

    The study of circulating tumor cells (CTCs) has a huge clinical interest in advance and metastatic breast cancer patients. However, many approaches are biased by the use of epithelial markers, which underestimate non-epithelial CTCs phenotypes. CTCs enumeration provides valuable prognostic information; however, molecular characterization could be the best option to monitor patients throughout the disease since it may provide more relevant clinical information to the physicians. In this work, we aimed at enumerating and performing a molecular characterization of CTCs from a cohort of 20 patients with metastatic breast cancer (MBC), monitoring the disease at different time points of the therapy, and at progression when it occurred. To this end, we used a CTC negative enrichment protocol that allowed us to recover a higher variety of CTCs phenotypes. With this strategy, we were able to obtain gene expression data from CTCs from all the patients. In addition, we found that high expression levels of PALB2 and MYC were associated with a worse outcome. Interestingly, we identified that CTCs with an EpCAMhighVIMlowALDH1A1high signature showed both shorter overall survival (OS) and progression-free survival (PFS), suggesting that CTCs with epithelial-stem features had the most aggressive phenotype.